Raymond James Financial’s Pacira BioSciences PCRX Stock Holding History

Raymond James Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Sell	40,082 -12,595	-24%	-$298K	﹤0.01%	3978
2026 Q1	$1.19M	Buy	52,677 +35,121	+200%	+$781K	﹤0.01%	3740
2025 Q4	$454K	Buy	+17,556	New	+$417K	﹤0.01%	4334
2025 Q3	–	Sell	-90,108	Closed	-$2.15M	–	6231
2025 Q2	$2.15M	Buy	90,108 +76,411	+558%	+$1.93M	﹤0.01%	3028
2025 Q1	$340K	Buy	13,697 +3,598	+36%	+$86.1K	﹤0.01%	4143
2024 Q4	$190K	Buy	+10,099	New	+$177K	﹤0.01%	4416

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's PCRX Position: Q2 2026 in Review

Raymond James Financial reduced its Pacira BioSciences (PCRX) stake by 24% in Q2 2026, selling an estimated $298K and leaving 40,082 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3978.

Raymond James Financial first reported a position in PCRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.15M in Q2 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Raymond James Financial held 40,082 shares of Pacira BioSciences worth $1.02M as of Q2 2026.
Raymond James Financial sold 12,595 Pacira BioSciences shares in Q2 2026, an estimated $298K.
Pacira BioSciences made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3978 holding.
Raymond James Financial first reported a position in Pacira BioSciences in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Pacira BioSciences position peaked at $2.15M in Q2 2025.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.